AI illustration · not actual product photoDetails from the source.
This catalogue entry records AHK-Cu, 100 mg × 10 vials (SKU AK100), using the supplied source listing. The cited dossier describes: The direct AHK-Cu research located concerns hair-follicle biology, including ex-vivo human follicle tissue and cultured dermal papilla cells. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- AK100
- Source specification
- 100mg*10vials
- Source document
- PriceList(1).pdf, page 3
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
AHK-Cu is described in a peer-reviewed study as a copper(II) complex of the tripeptide L-alanyl-L-histidyl-L-lysine; it is a peptide complex. The scientific name does not verify the identity or formulation of this exact supplier vial. The supplied PriceList(1).pdf lists SKU AK100, *10vials, price 63 per 10 vials (currency not stated).
Biological mechanism
A 2007 laboratory study reported increased proliferation of cultured human dermal papilla cells and changes in cell-survival markers; it also observed elongation of excised human hair follicles ex vivo. Authors proposed a relationship between dermal papilla cell effects and follicle elongation. This does not establish a mechanism in people or confirm the listed vial's contents. [1]
Research focus
The direct AHK-Cu research located concerns hair-follicle biology, including ex-vivo human follicle tissue and cultured dermal papilla cells. [1]
Potential applications in the evidence
AHK-Cu has been investigated in laboratory models of hair-follicle growth. These findings do not establish a treatment application or clinical benefit in people. Evidence about other copper peptides, including GHK-Cu, is not proof for AHK-Cu or this listed vial.
Human evidence
The identified primary study used excised human hair follicles ex vivo and cultured cells in vitro, not human participants. A ClinicalTrials.gov search for “Copper Peptide AHK-Cu” returned no records when checked; registry searches can miss studies, so this does not prove none exist. The identified laboratory evidence has not established clinical benefit, an effective use, or human safety. [1] [2]
Known and potential effects
The laboratory study reported follicle elongation ex vivo and cell proliferation and changes in cell-survival markers in cultured cells. It does not establish an adverse-effect profile in people. No specific adverse effects for this exact vial could be verified. [1]
Safety and contraindications
Human safety data and the exact product identity are unverified. The source materials do not establish risks, contraindications, interactions, sterility, contaminants, or suitability for any exposure route. Do not infer safety from laboratory findings. No specific contraindication for this exact item could be verified.
U.S. FDA / regulatory status
A search of FDA's Drugs@FDA approval resource did not identify an FDA-approved AHK-Cu drug. Drugs@FDA has stated scope and limitations, and absence from a search does not establish the status of this supplier-specific vial. FDA notes that cosmetic products and ingredients generally do not require premarket FDA approval; this does not show that the listed vial is a cosmetic. The supplied PDF does not identify a manufacturer, lot, formulation source, jurisdiction, or approval. Its approval, approved-branded-formulation status, compounding status, and research-only status cannot be verified; do not transfer any active-ingredient or other product approval to it. [3] [4]
Evidence limitations
The directly relevant evidence located is a single 2007 in-vitro/ex-vivo study. Laboratory results do not establish outcomes, safety, or effectiveness in people. The catalogue provides no product-specific analytical documentation linking the listed vial to the study material. The ClinicalTrials.gov query is a registry search, not a comprehensive proof of absent research.
Supporting sources
- The effect of tripeptide-copper complex on human hair growth in vitro PubMed / Archives of Pharmacal Research · Peer-reviewed primary study record and abstract. Supports: Peptide-complex identity and the in-vitro/ex-vivo study methods and findings; does not demonstrate a human clinical effect or clinical safety.
- ClinicalTrials.gov search for Copper Peptide AHK-Cu U.S. National Library of Medicine · Government clinical-trial registry search. Supports: The query returned no matching records when checked; supports only a qualified registry-search statement, not proof that no human studies exist.
- About Drugs@FDA U.S. Food and Drug Administration · Official FDA database scope information. Supports: Explains the Drugs@FDA approved-product database scope and limitations relevant to describing the search for an approved AHK-Cu drug.
- Cosmetic Ingredients U.S. Food and Drug Administration · Official FDA regulatory information. Supports: Explains that most cosmetic products and ingredients do not require premarket FDA approval; does not establish that this vial is a cosmetic.